Market Closed -
Nasdaq
02:00:01 04/05/2024 am IST
|
5-day change
|
1st Jan Change
|
1.38
USD
|
0.00%
|
|
+3.76%
|
-15.34%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
92.2
|
116.3
|
185
|
128
|
86.96
|
75.43
|
-
|
-
|
Enterprise Value (EV)
1 |
-22.43
|
35.68
|
74.37
|
44.07
|
86.96
|
20.99
|
64.84
|
75.43
|
P/E ratio
|
-1.72
x
|
-3.27
x
|
-3.81
x
|
-4.32
x
|
-1.89
x
|
-1.4
x
|
-1.49
x
|
-1.89
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
1,378
x
|
81
x
|
34
x
|
47.1
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
1,378
x
|
22.5
x
|
29.3
x
|
47.1
x
|
EV / EBITDA
|
3,99,872
x
|
-10,73,762
x
|
-15,83,529
x
|
-13,92,696
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
0.51
x
|
-0.97
x
|
-1.86
x
|
-1.3
x
|
-
|
-0.33
x
|
-0.95
x
|
-5.62
x
|
FCF Yield
|
195%
|
-103%
|
-53.8%
|
-76.9%
|
-
|
-302%
|
-105%
|
-17.8%
|
Price to Book
|
0.86
x
|
1.49
x
|
1.76
x
|
1.45
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
26,105
|
28,228
|
44,186
|
44,204
|
58,883
|
58,883
|
-
|
-
|
Reference price
2 |
3.532
|
4.118
|
4.187
|
2.897
|
1.477
|
1.281
|
1.281
|
1.281
|
Announcement Date
|
29/04/20
|
25/03/21
|
24/03/22
|
22/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
0.0631
|
0.9317
|
2.216
|
1.6
|
EBITDA
|
-56.11
|
-33.23
|
-46.97
|
-31.64
|
-
|
-
|
-
|
-
|
EBIT
1 |
-56.77
|
-33.94
|
-47.63
|
-32.24
|
-44.91
|
-58.99
|
-66.94
|
-57.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-71,181.01%
|
-6,331.32%
|
-3,020.28%
|
-3,581.33%
|
Earnings before Tax (EBT)
1 |
-53.25
|
-33.98
|
-45.63
|
-29.48
|
-42.67
|
-60.52
|
-66.9
|
-56.61
|
Net income
1 |
-53.25
|
-33.98
|
-45.63
|
-29.48
|
-42.67
|
-58.06
|
-62.86
|
-56.32
|
Net margin
|
-
|
-
|
-
|
-
|
-67,629.62%
|
-6,232.33%
|
-2,836.03%
|
-3,519.75%
|
EPS
2 |
-2.050
|
-1.260
|
-1.100
|
-0.6700
|
-0.7800
|
-0.9175
|
-0.8625
|
-0.6767
|
Free Cash Flow
1 |
-43.8
|
-36.62
|
-39.97
|
-33.91
|
-
|
-63.31
|
-68.02
|
-13.42
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-6,795.22%
|
-3,069.17%
|
-838.81%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/04/20
|
25/03/21
|
24/03/22
|
22/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.0608
|
0.00229
|
0.1323
|
0.1227
|
0.129
|
0.5477
|
-
|
EBITDA
|
-12.57
|
-12.83
|
-14.71
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-12.73
|
-13
|
-14.86
|
-1.087
|
-8.594
|
-7.699
|
-10.59
|
-9.856
|
-11.15
|
-13.31
|
-13
|
-15.15
|
-15.65
|
-15.26
|
-13.98
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-18,340.21%
|
-5,81,058.52%
|
-9,820.4%
|
-12,349.94%
|
-12,130.49%
|
-2,786.41%
|
-
|
Earnings before Tax (EBT)
1 |
-12.05
|
-12.67
|
-14
|
0.4654
|
-7.922
|
-8.026
|
-11.08
|
-8.202
|
-7.451
|
-15.93
|
-13.44
|
-15.56
|
-16.01
|
-15.57
|
-13.29
|
Net income
1 |
-12.05
|
-12.67
|
-14
|
0.4654
|
-7.922
|
-8.026
|
-11.08
|
-8.202
|
-7.451
|
-15.93
|
-13.25
|
-14.84
|
-15.18
|
-14.85
|
-13.29
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-12,255.61%
|
-6,95,640.17%
|
-10,015.49%
|
-12,096.89%
|
-11,764.92%
|
-2,710.62%
|
-
|
EPS
2 |
-0.2700
|
-0.2900
|
-0.3200
|
0.0100
|
-0.1800
|
-0.1800
|
-0.2500
|
-0.1400
|
-0.1300
|
-0.2800
|
-0.2225
|
-0.2475
|
-0.2350
|
-0.2150
|
-0.1900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
05/11/21
|
24/03/22
|
12/05/22
|
05/08/22
|
09/11/22
|
22/03/23
|
11/05/23
|
10/08/23
|
01/11/23
|
21/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
115
|
80.6
|
111
|
84
|
-
|
54.4
|
10.6
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-43.8
|
-36.6
|
-40
|
-33.9
|
-
|
-63.3
|
-68
|
-13.4
|
ROE (net income / shareholders' equity)
|
-41.2%
|
-36.7%
|
-49.8%
|
-30.5%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-37.9%
|
-32.4%
|
-42.8%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
140.4
|
104.9
|
106.7
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
4.120
|
2.760
|
2.380
|
2.000
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-1.350
|
-0.9600
|
-0.7600
|
-
|
-
|
-
|
-
|
Capex
1 |
0.59
|
0.09
|
0.04
|
0.16
|
-
|
0.09
|
0.1
|
0.12
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
9.55%
|
4.42%
|
7.38%
|
Announcement Date
|
29/04/20
|
25/03/21
|
24/03/22
|
22/03/23
|
21/03/24
|
-
|
-
|
-
|
Last Close Price
1.281
EUR Average target price
7.372
EUR Spread / Average Target +475.48% Consensus |
1st Jan change
|
Capi.
|
---|
| -15.34% | 81.26M | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +38.61% | 12.63B | | +313.59% | 8.49B |
Bio Therapeutic Drugs
|